(Q35096206)

6 August 2017

1 reference

title

Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets (English)

1 reference

6 August 2017

Donald M Coen

1

1 reference

6 August 2017

Priscilla A Schaffer

series ordinal

2

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Nature Reviews Drug Discovery

6 August 2017

published in

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

278-288

1 reference

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

6 August 2017

cites work

1 reference

Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics

31 March 2020

1 reference

Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.

31 March 2020

1 reference

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis

31 March 2020

1 reference

Modified entry and syncytium formation by herpes simplex virus type 1 mutants selected for resistance to heparin inhibition

31 March 2020

1 reference

Safety and efficacy of Virend for topical treatment of genital and anal herpes simplex lesions in patients with AIDS

31 March 2020

1 reference

Three classes of cell surface receptors for alphaherpesvirus entry

31 March 2020

1 reference

Herpes simplex virus glycoprotein D bound to the human receptor HveA

31 March 2020

1 reference

Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

31 March 2020

1 reference

Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)

31 March 2020

1 reference

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2.

31 March 2020

1 reference

Identification and characterization of a benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection

31 March 2020

1 reference

Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses

31 March 2020

1 reference

Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors

31 March 2020

1 reference

Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents

31 March 2020

1 reference

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

31 March 2020

1 reference

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

31 March 2020

1 reference

Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2.

31 March 2020

1 reference

Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides

31 March 2020

1 reference

Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation

31 March 2020

1 reference

A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo

31 March 2020

1 reference

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity

31 March 2020

1 reference

Role of the carboxy terminus of herpes simplex virus type 1 DNA polymerase in its interaction with UL42.

31 March 2020

1 reference

Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface

31 March 2020

1 reference

Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin.

31 March 2020

1 reference

The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase

31 March 2020

1 reference

Identification of crucial hydrogen-bonding residues for the interaction of herpes simplex virus DNA polymerase subunits via peptide display, mutational, and calorimetric approaches

31 March 2020

1 reference

A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site

31 March 2020

1 reference

Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad.

31 March 2020

1 reference

Three-dimensional structure of human cytomegalovirus protease

31 March 2020

1 reference

Unique fold and active site in cytomegalovirus protease

31 March 2020

1 reference

A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease

31 March 2020

1 reference

The antiviral agent 5-chloro-1,3-dihydroxyacridone interferes with assembly and maturation of herpes simplex virus

31 March 2020

1 reference

Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene

31 March 2020

1 reference

Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation

31 March 2020

1 reference

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action

31 March 2020

1 reference

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products

31 March 2020

1 reference

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

31 March 2020

1 reference

Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position

31 March 2020

1 reference

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

31 March 2020

1 reference

Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation

31 March 2020

1 reference

Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase

31 March 2020

1 reference

Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.

31 March 2020

1 reference

Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy

31 March 2020

1 reference

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

31 March 2020

1 reference

Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication

31 March 2020

1 reference

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

31 March 2020

1 reference

Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication

31 March 2020

1 reference

Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy

31 March 2020

1 reference

Cyclin-dependent kinases as cellular targets for antiviral drugs

31 March 2020

1 reference

EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus

31 March 2020

1 reference

Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers

31 March 2020

1 reference

Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes

31 March 2020

1 reference

Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease

31 March 2020

1 reference

Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates

31 March 2020

1 reference

7 January 2021

inferred from DOI database lookup

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

1 reference

7 January 2021

inferred from DOI database lookup

Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRD1065

1 reference

release_aytgqddcjbfm7llzb5znhpiyda

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aytgqddcjbfm7llzb5znhpiyda

24 November 2022

mapped directly with Wikidata item

1 reference